INHIBITORS OF THE INTERACTION OF THE UPAR/FPRS RECEPTORS
The compoundwherein R1 is selected from amongst: H, Me, OH; R2 is selected from amongst: H, OH, Me, t-Bu, Et, OMe, Pr, Allyl; R3 is selected from amongst: H, OH, Me, Cl, F; R4 is selected from amongst: H, Me, Ome, t-Bu, Cl; R5 is selected from amongst: H, OH, Me, OMe; R6 is selected from amongst: H, Me, OH, OMe; R7 is selected from the group consisting of: H, Me, OMe, t-Bu, Cl; R8 is selected from the group consisting of: OH, Me, H, F; R9 is selected from the group consisting of; OH, Me, H, t-Bu, Et, OMe, Pr, Allyl; R10 is selected from the group consisting of: H, Me, OH; and X is either absent or is selected from the group consisting of:, CO, CH2,, for use in a method for treating pathologies mediated by the interaction of the uPAR/FPRs receptors..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 18. Mai Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
DE PAULIS AMATO [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-05-18, Last update posted on www.tib.eu: 2023-06-23, Last updated: 2023-06-30 |
|---|
| Patentnummer: |
US2023149323 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA017252865 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA017252865 | ||
| 003 | DE-627 | ||
| 005 | 20230630123120.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230623s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA017252865 | ||
| 035 | |a (EPA)US2023149323 | ||
| 035 | |a (EPA)71170733 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a DE PAULIS AMATO |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a INHIBITORS OF THE INTERACTION OF THE UPAR/FPRS RECEPTORS |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-05-18, Last update posted on www.tib.eu: 2023-06-23, Last updated: 2023-06-30 | ||
| 520 | |a The compoundwherein R1 is selected from amongst: H, Me, OH; R2 is selected from amongst: H, OH, Me, t-Bu, Et, OMe, Pr, Allyl; R3 is selected from amongst: H, OH, Me, Cl, F; R4 is selected from amongst: H, Me, Ome, t-Bu, Cl; R5 is selected from amongst: H, OH, Me, OMe; R6 is selected from amongst: H, Me, OH, OMe; R7 is selected from the group consisting of: H, Me, OMe, t-Bu, Cl; R8 is selected from the group consisting of: OH, Me, H, F; R9 is selected from the group consisting of; OH, Me, H, t-Bu, Et, OMe, Pr, Allyl; R10 is selected from the group consisting of: H, Me, OH; and X is either absent or is selected from the group consisting of:, CO, CH2,, for use in a method for treating pathologies mediated by the interaction of the uPAR/FPRs receptors. | ||
| 650 | 4 | |a che | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a LAVECCHIA ANTONIO |4 aut | |
| 700 | 0 | |a MONTUORI NUNZIA |4 aut | |
| 700 | 0 | |a ROSSI FRANCESCA WANDA |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 18. Mai |
| 773 | 1 | 8 | |g year:2023 |g day:18 |g month:05 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/71170733/publication/US2023149323A1?q=US2023149323 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2023 |b 18 |c 05 |
| 951 | |a AR | ||
| 952 | |j 2023 |b 18 |c 05 | ||